Abstract
AbstractThe melanocortin-4 receptor (MC4R), a hypothalamic master regulator of energy homeostasis and appetite, is a class A G-protein-coupled receptor and a prime target for the pharmacological treatment of obesity. Here, we present cryo-electron microscopy structures of MC4R–Gs-protein complexes with two drugs recently approved by the FDA, the peptide agonists NDP-α-MSH and setmelanotide, with 2.9 Å and 2.6 Å resolution. Together with signaling data from structure-derived MC4R mutants, the complex structures reveal the agonist-induced origin of transmembrane helix (TM) 6-regulated receptor activation. The ligand-binding modes of NDP-α-MSH, a high-affinity linear variant of the endogenous agonist α-MSH, and setmelanotide, a cyclic anti-obesity drug with biased signaling toward Gq/11, underline the key role of TM3 in ligand-specific interactions and of calcium ion as a ligand-adaptable cofactor. The agonist-specific TM3 interplay subsequently impacts receptor–Gs-protein interfaces at intracellular loop 2, which also regulates the G-protein coupling profile of this promiscuous receptor. Finally, our structures reveal mechanistic details of MC4R activation/inhibition, and provide important insights into the regulation of the receptor signaling profile which will facilitate the development of tailored anti-obesity drugs.
Funder
Deutsche Forschungsgemeinschaft
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology
Reference66 articles.
1. Wikberg, J. E. & Mutulis, F. Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nat. Rev. Drug Discov. 7, 307–323 (2008).
2. Krashes, M. J., Lowell, B. B. & Garfield, A. S. Melanocortin-4 receptor-regulated energy homeostasis. Nat. Neurosci. 19, 206–219 (2016).
3. Heyder, N. et al. Signal transduction and pathogenic modifications at the melanocortin-4 receptor: A structural perspective. Front. Endocrinol. 10, 515 (2019).
4. Biebermann, H., Kuhnen, P., Kleinau, G. & Krude, H. The neuroendocrine circuitry controlled by POMC, MSH, and AGRP. Handb. Exp. Pharmacol. 209, 47–75 (2012).
5. Nijenhuis, W. A., Oosterom, J. & Adan, R. A. AgRP(83-132) acts as an inverse agonist on the human melanocortin-4 receptor. Mol. Endocrinol. 15, 164–171 (2001).
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献